18:34:21 EST Thu 19 Nov 2026
Enter Symbol
or Name
USA
CA



Vesalius Longevity Labs Inc
Symbol VLAB
Shares Issued 107,019,422
Close 2026-11-19 C$ 1.62
Market Cap C$ 173,371,464
Recent Sedar+ Documents

Vesalius Longevity appoints Diamandis director

2026-11-19 16:28 ET - News Release

Mr. Harvey Spevak reports

VESALIUS LONGEVITY LABS APPOINTS LONGEVITY ENTREPRENEUR DR. PETER DIAMANDIS TO ITS BOARD OF DIRECTORS

Vesalius Longevity Labs Inc. has appointed Dr. Peter Diamandis to its board of directors, effective Nov. 19, 2026.

Dr. Diamandis is a highly recognized entrepreneur and thought-leader in longevity, exponential technology and health innovation. He is the founder and executive chairman of the XPrize Foundation; the executive founder of Singularity University; co-founder and chairman of Fountain Life, an integrated longevity and preventative health platform; and co-founder of Bold Capital Partners, a venture fund investing in exponential technologies. Over his career, Dr. Diamandis has founded more than 25 companies across health-tech, space, venture capital and education.

Dr. Diamandis holds degrees in molecular genetics and aerospace engineering from the Massachusetts Institute of Technology and an M.D. from Harvard Medical School. He is a New York Times best-selling author whose books include Abundance: The Future Is Better Than You Think, Bold: How to Go Big, Create Wealth & Impact the World, The Future Is Faster Than You Think, and the No. 1 best-seller Life Force, co-authored with Tony Robbins. Fortune has named him one of the "World's 50 Greatest Leaders."

As a director, Dr. Diamandis will support Vesalius's strategy across its peptide and longevity platform, scientific and clinical positioning, and strategic partnerships as the company scales its provider network and brand globally.

With the appointment of Dr. Diamandis, the board now includes Harvey Spevak (chairman), David Adelman, Kevin Mayer, Lee Applbaum, Kevin Serre, Robert McCue and James McRoberts.

The company also announces that Joel Leonoff has stepped down from the board, effective Nov. 19, 2026.

RSU grants

The company also announces that it has granted a total of 6.3 million restricted share units to certain directors, officers and consultants of the company pursuant to the company's 10-per-cent rolling RSU plan.

Each RSU expires three years from the grant date. Of the RSUs granted, 1.75 million vest immediately on the grant date, 1,137,500 vest six months following the grant date, 1,537,500 vest 12 months following the grant date, 937,500 vest eighteen 18 months following the grant date and 937,500 vest 24 months following the grant date.

About Vesalius Longevity Labs Inc.

Vesalius Longevity Labs is a longevity and regenerative health platform focused on peptides, biologics and preventative health care. Vesalius's proprietary ecosystem is designed to connect health-care providers with trusted, compliant pharmacies and support the people they serve with access to quality therapies, education and partnerships.

We seek Safe Harbor.

© 2026 Canjex Publishing Ltd. All rights reserved.